Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitor in ACS Patients with Multivessel Disease (CHOICE)
NCT05043740Unknown
- Sponsor
- The Second Xiangya Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of evolocumab and alirocumab in acute coronary syndrome (ACS) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Major Adverse Cardiac Events at 12 months. Status: unknown.
02
Drugs
evolocumabalirocumab
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05043740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043740.